3bnc117

mAbexperimental

Clinical trial activity

30 trials · 34 clinical orgs · 0 marketing orgs

Phase 1
19
Phase 2
14
Phase 3
0
Phase 4
0

Earliest trial started Jan 1, 2014 (NCT02018510)

Timeline

2010s

  1. Jan 1, 2014

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2015

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 3bnc117
  • 3bnc117-ls

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07054931Phase 2Sep 5, 2025University of Oxford
NCT06205602Phase 2Oct 15, 2024National Institute of Allergy and Infectious Diseases (NIAID)
NCT06071767Phase 1/Phase 2 (Phase 2)Jan 2, 2024Gilead Sciences, National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford, University of Pittsburgh
NCT06031272Phase 1Dec 4, 2023AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID)
NCT05729568Phase 2May 15, 2023Gilead Sciences
NCT05612178Phase 1Dec 29, 2022National Institute of Allergy and Infectious Diseases (NIAID)
NCT05245292Phase 1Dec 15, 2022Cornell University, National Institute of Allergy and Infectious Diseases (NIAID), Rockefeller University, University of Pennsylvania
NCT05079451Phase 1Nov 1, 2021National Institute of Allergy and Infectious Diseases (NIAID), Rockefeller University, University of Pennsylvania
NCT04819347Phase 2May 1, 2021Frontier Biotechnologies Co., Ltd.
NCT04811040Phase 1Apr 8, 2021Gilead Sciences
NCT04720742Phase 2Feb 28, 2021Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milano, Hospital General Universitario Gregorio Marañon, IrsiCaixa, University of Granada, Utrecht University
NCT04560569Phase 2Dec 25, 2020Frontier Biotechnologies Co., Ltd.
NCT04250636Phase 1Feb 28, 2020Cornell University, National Institute of Allergy and Infectious Diseases (NIAID), Rockefeller University, University of Pennsylvania
NCT04173819Phase 1/Phase 2 (Phase 2)Dec 1, 2019International AIDS Vaccine Initiative, Rockefeller University, University of Washington
NCT03837756Phase 2May 6, 2019Aalborg University, Aarhus University, The Peter Doherty Institute, University of Copenhagen, University of Southern Denmark, University of Utah
NCT03719664Phase 2Dec 17, 2018Frontier Biotechnologies Co., Ltd.
NCT03571204Phase 1Sep 10, 2018National Institute of Allergy and Infectious Diseases (NIAID)
NCT03588715Phase 1Aug 1, 2018Merck, National Institute of Allergy and Infectious Diseases (NIAID), Philadelphia Fight, Rockefeller University, The Wistar Institute, University of Pennsylvania
NCT03554408Phase 1Jun 30, 2018Rockefeller University
NCT03526848Phase 1Jun 5, 2018National Institute of Allergy and Infectious Diseases (NIAID), Ragon Institute of MGH, MIT and Harvard, Rockefeller University, Yeshiva University
Showing 20 of 30 trials
Page 1 / 2

Organizations

Research & Development (34)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Rockefeller UniversityAcademic/Hospital151122014
National Institute of Allergy and Infectious Diseases (NIAID)Government11622015
Cornell UniversityAcademic/Hospital4022014
University of CologneAcademic/Hospital4022014
University of PennsylvaniaAcademic/Hospital4012018
Aarhus UniversityAcademic/Hospital3212016
Frontier Biotechnologies Co., Ltd.For profit3312018
Gilead SciencesFor profit3222021
Aalborg UniversityAcademic/Hospital2012017
The Peter Doherty InstituteAcademic/Hospital2022017
University of CopenhagenAcademic/Hospital2012017
University of OxfordAcademic/Hospital2112024
University of Southern DenmarkAcademic/Hospital2012017
Yeshiva UniversityAcademic/Hospital2022015
AIDS Clinical Trials GroupAcademic/Hospital1112023
Austin HealthAcademic/Hospital1012017
Bill and Melinda Gates FoundationAcademic/Hospital1012015
Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, MilanoAcademic/Hospital1012021
Harvard UniversityAcademic/Hospital1012014
Herning HospitalAcademic/Hospital1012017
34 organizations
Page 1 / 2